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Context:Maternal obesity is associated with high plasma triglyceride, poor vascular function, and
an increased risk for pregnancy complications. In normal-weight pregnant women, higher triglyc-
eride is associated with increased small, dense low-density lipoprotein (LDL).
Hypothesis: In obese pregnancy, increased plasma triglyceride concentrations result in triglyceride
enrichment of very low-density lipoprotein-1 particles and formation of small dense LDL via lipo-
protein lipase.
Design: Women (n  55) of body mass index of 18–46 kg/m2 were sampled longitudinally at 12,
26, and 35 weeks’ gestation and 4 months postnatally.
Setting: Women were recruited at hospital antenatal appointments, and study visits were in a
clinical research suite.
Outcome Measures: Plasma concentrations of lipids, triglyceride-rich lipoproteins, lipoprotein
lipase mass, estradiol, steroid hormone binding globulin, insulin, glucose, leptin, and adiponectin
were determined.
Results:Obese women commenced pregnancy with higher plasma triglyceride, reached the same
maximum, and then returned to higher postnatal levels than normal-weight women. Estradiol
response to pregnancy (trimester 1–3 incremental area under the curve) was positively associated
withplasma triglyceride response (r2 adjusted 25%,P .001). In the third trimester, theproportion
of small, dense LDLwas 2-foldhigher inobesewomen thannormal-weightwomen [mean (SD) 40.7
(18.8) vs 21.9 (10.9)%, P .014], and 35% of obese, 14% of overweight, and none of the normal-
weight women displayed an atherogenic LDL subfraction phenotype. The small, dense LDL mass
response to pregnancy was inversely associated with adiponectin response (17%, P  .013).
Conclusions: Maternal obesity is associated with an atherogenic LDL subfraction phenotype and
may provide a mechanistic link to poor vascular function and adverse pregnancy outcome. (J Clin
Endocrinol Metab 98: 643–652, 2013)
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Abbreviations: AUC, Area under the curve; BMI, body mass index; GDM, gestational di-
abetes mellitus; HOMA, homeostasis model assessment; IDL, intermediate-density lipo-
protein; LDL, low-density lipoprotein; LDL-III, small, dense LDL; LPL, lipoprotein lipase;
NEFA, nonesterified fatty acid; PE, preeclampsia; PN, postnatal samples; T1, trimester 1; T2,
trimester 2; T3, trimester 3; TG, triglycerides; VLDL, very low-density lipoprotein.
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Obesity in the pregnant population has increased by70%–100% over a decade and 1 in 5 pregnant
women in the United Kingdom is obese (1). The conse-
quences include increased risk ofmetabolic complications
such as preeclampsia (PE) and gestational diabetes melli-
tus (GDM),whichalso impacton fetalmorbidityandmor-
tality (2).Dysregulationofmaternal lipidmetabolismmay
be an underlying component in the etiology of PE and
GDM (3, 4). Maternal obesity has also been linked to the
development of obesity in offspring via a fetal oversupply
of glucose and/or lipids in utero (5).
Maternal adaptation to pregnancy includes increased
storage of fatty acids in adipose tissue in early gestation,
and mobilization of fatty acids from adipose tissue in re-
sponse to maternal insulin resistance induced by preg-
nancyhormones, inmid- to late gestation (6).Obesemoth-
ers have higher fasting insulin, plasma triglycerides (TGs),
and lower high-density lipoprotein concentrations in the
third trimester of pregnancy in combination with in-
creased markers of inflammation (7). Thus, the physio-
logically normal insulin resistance is much more pro-
nounced in overweight and obese women. Obese women
also have a compromised vascular adaptation to preg-
nancy, and vascular function fails to show the same extent
of improvement as that of normal-weight pregnant
women (8). The combination of an adverse metabolic/
inflammatory profile and vascular dysfunction may im-
pact on both placental development and the maternal re-
sponse to pregnancy, leading to adverse outcomes such as
GDM and PE (9).
The major TG-carrying particle in the circulation is
very low-density lipoprotein (VLDL), which can be frac-
tionated into 2 structurally andmetabolically distinct sub-
fractions; large TG-rich VLDL-1 and smaller VLDL-2.
Triglyceride in these particles is hydrolyzed by lipases,
resulting in the formation of smaller particles (10). Non-
pregnant obesity is characterized by an increase in plasma
VLDL concentration, predominantly due to VLDL-1, an
increase in intermediate-density lipoprotein (IDL) and a
shift in low-density lipoprotein (LDL) size distribution to-
ward smaller, denser lipoproteins (11). An increased pro-
portion of small, dense LDL (LDL-III) is indicative of an
atherogenic lipoprotein phenotype (12) and has been
associated with hepatic steatosis (13, 14). In a study
of 10 normal-weight pregnant women, VLDL-1 and
VLDL-2 subfractions increased in parallel by up to
5-fold throughout gestation (15). Plasma LDL concen-
tration rose by up to 70%, and in some women there
was a shift toward smaller, denser LDL particles, which
was associated with TG concentration at 10 weeks’ ges-
tation and the rate of change in TG for a given increment
in estrogen (15).
We have previously suggested that GDM and PE may
result from inappropriate handling of the increased TG
turnoverof pregnancy, leading toan ectopic accumulation
of fat, particularly in the liver (9, 16), and formation of an
atherogenic lipoprotein profile. Although plasma TG lev-
els and the proportion of small, dense LDL have been
shown to be higher in GDM (17) and PE (18) compared
withnormal-weightpregnantwomen, there arenodataon
small, dense LDL in obese pregnancy. We hypothesized
that in obese pregnancy, increased plasma TG concentra-
tions result in TG enrichment of large VLDL-1 particles,
which are a precursor for the formation of small, dense
LDL via the action of plasma lipoprotein lipase (LPL). In
this study,we followedup gestational changes inmaternal
VLDL and LDL concentrations and subfraction distribu-
tion in women of different body mass index (BMI). LPL
mass and hormone/adipokine concentrations were also
assessed in relation to the lipid and lipoprotein changes.
Materials and Methods
Patient recruitment
Women (n  55) registered for obstetric care at the Princess
Royal Maternity Unit (Glasgow, United Kingdom) who were
healthy and normotensive with no significant past medical his-
tory were recruited. Normal-weight individuals were those with
a booking BMI less than 25 kg/m2, overweight with BMI 25
kg/m2 or greater but less than 30 kg/m2, and obese with BMI 30
kg/m2 or greater. The study was performed according to the
Declaration of Helsinki, approval was granted by the Research
EthicsCommittee ofNorthGlasgowUniversityNationalHealth
Service Trust, and each subject gave written informed consent.
The women attended after an overnight fast (10 h). Blood
samples were collected into 1 mg/mL EDTA at a mean of 12.5
[range 8–14) (T1), 26.1 (24–28) (T2), and 35.5 (33–38) (T3)]
weeks’ gestation and plasma collected by low-speed centrifuga-
tion. Postnatal samples (PN) were collected 17.1 (12–26) weeks
after delivery. Maternal booking (ie, first antenatal hospital ap-
pointment) characteristics and delivery details were recorded
from the patients’ notes. Birth weights were normalized by ges-
tation at birth, fetal sex, and maternal parity. Deprivation cat-
egory score, a measure of socioeconomic status, was assigned
using the Scottish Area Deprivation Index for Scottish postcode
sectors, 1998 (19).
Maternal plasma lipids and lipoproteins
Plasma total cholesterol and TG concentrations and VLDL-1
(Sf 60–400), VLDL-2 (Sf 20–60), IDL (Sf 12–20), and LDL (Sf
0–12) concentration and composition were determined as de-
scribed (15). Plasma nonesterified fatty acid (NEFA) concentra-
tion was quantitated by colorimetric assay (Wako, Alpha Lab-
oratories, Eastleigh, United Kingdom). The milligrams TG to
milligrams cholesteryl ester ratio was used as an index of the
TG-carrying capacity of each particle. Isolation of LDL subfrac-
tions from plasma was achieved by density gradient ultracen-
trifugation using a discontinuous salt gradient (15, 20) and re-
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ported as mass concentration and percentage abundance.
Subjects were classified as having the atherogenic LDL subfrac-
tion profile, pattern B,when LDL-III was greater than 50% (21).
Hormone and lipoprotein lipase measurement
Plasma estradiol was estimated using the Immunulite semi-
automated assay system (Diagnostic Products Corp, Los Ange-
les, California). Insulin (Mercodia, Uppsala, Sweden), leptin,
and adiponectin (R&D Systems, Abingdon, United Kingdom)
and SHBG (IBL, Hamburg, Germany) analyses were performed
by ELISA. Homeostasis model assessment (HOMA) was calcu-
lated as [fasting insulin (milliunits per liter)  fasting glucose
(millimoles per liter)]/22.5. LPL mass was determined by ELISA
using bovine LPL as standard (22, 23). LPL genotype was de-
termined by allelic discrimination analysis on a 7900 HT se-
quence detection system (Applied Biosystems, Paisley, United
Kingdom) using a Taqman single-nucleotide polymorphism
genotyping assay (C_901792_1).
Statistical analysis
Values for continuous variables are given as mean (SD) and
number (percentage) for categorical variables. Total and incre-
mental areas under the time (T1 to T3 weeks’ gestation) con-
centration curve were calculated using the trapezium method
with correction forbaseline (T1)parameter level (24).Normality
testing was carried out using the Ryan-Joiner test, and data were
log or square root transformed to achieve a normal distribution
as necessary. One-way ANOVA or a 2 test was used when
assessing the whole group for differences between time (with
repeated measures) or the BMI group. Simultaneous difference
testing between BMI group across time points was carried out
using a univariate split-plot approach, repeated-measures
analysis with a post hoc ANOVA for specific time/BMI cat-
egory differences. Associations between variables were exam-
ined using a univariate regression analysis. Statistical analysis
used the JMP statistical analysis program (version 5.1; SAS
Institute, Cary, North Carolina).
Results
Patient characteristics
Characteristics of the women at the booking visit and
offspring characteristics at delivery are shown in Table 1.
Normal-weightwomenwere, on average, 2 years younger
than heavier-weight women. As expected, the BMI, sys-
tolic and diastolic blood pressure was significantly higher
in higher BMI categories. Gestation at delivery did not
differ between the 3 groups. Placental weight, birth
weight, and birth weight centile of offspring increased
with increasing maternal booking BMI.
Plasma lipids and lipoproteins
Plasma total and LDL cholesterol increased fromT1 to
T3 and declined in the postnatal period (P .001), but the
maternal BMI category had no impact on these changes
(Table 2). Plasma TG increased over gestation and de-
clined postnatally (P  .001), and the response differed
between BMI categories (P .030), with overweight and
obese women having higher plasma TG concentrations
Table 1. Maternal Antenatal Booking Characteristics According to the World Health Organization BMI Category
Normal Weight
(n  13)
Overweight
(n  15)
Obese
(n  27) P Value
Booking visit
Age, y* 27 (4)a 29 (6)a,b 29 (6)b .029
Smokers, n (%) 7 (54) 3 (20) 10 (37) .18
Deprivation index
DEPCAT score, n (%)
Affluent (1–2) 1 (8) 3 (20) 1 (4)
Intermediate (3–5) 5 (38) 3 (20) 10 (37) .74
Deprived (6–7) 7 (54) 9 (60) 16 (59)
Parity, n (%)
0 6 (46) 7 (47) 12 (44) .99
0 7 (54) 8 (53) 15 (56)
BMI, kg/m2* 21.2 (1.9)a 26.1 (1.0)b 33.7 (4.2)c .001
Systolic blood pressure, mm Hg* 107 (12)a 117 (9)b 124 (11)b .001
Diastolic blood pressure, mm Hg* 61 (6)a 68 (7)a,b 73 (10)b .001
LPL S447X genotype, SS:SX, n (%) 7:6 (54:46)a 14:1 (93:7)b 22:5 (81:19)a,b .035
At delivery
Gestation at delivery, wks* 39.6 (1.3) 39.9 (0.9) 40.0 (1.5) .46
Placental weight, g* 649 (143)a 817 (162)b 790 (177b .020
Birth weight, g* 3246 (521)a 3829 (533)b 3659 (512)a,b .015
Birth weight centile 38 (32)a 61 (34)a,b 74 (21)b .001
Abbreviation: DEPCAT, deprivation category. Values are mean and SD for continuous variables or number (percentage) for categorical variables.
ANOVA was used to test for differences among groups (*on log transformed where appropriate). A 2 test was used to test for differences among
groups for categorical variables. Different superscript letters indicate differences between individual groups using a post hoc Tukey-Kramer test or
subgroup 2 test. SS, homozygous for Serine at amino acid position 447 of LPL; SX, heterozygous for Serine and a stop codon at amino acid
position 447 of LPL.
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than normal-weight women. At a BMI of 20 kg/m2,
plasma TG concentration increases by 154% over gesta-
tion,whereas the increase is only 66%at aBMIof40kg/m2
(Supplemental Fig. 1, published on The Endocrine Society’s
JournalsOnlineweb site at http://jcem.endojournals.org). No-
tably, although the maximum plasma TG concentration
reached at T3 was similar, irrespective of BMI, obese women
expressed higher values at baseline.
Plasma NEFA levels did not change over gestation and
were unrelated tomaternal BMI. Themass concentrations
of VLDL, IDL, and LDL increased during pregnancy and
declined postnatally (all P  .001) (Table 2). However,
plasma VLDL concentration was significantly higher in
maternal obesity (P .016), with normal-weight women
having the lowest concentrations. There was an interac-
tion between trimester and BMI category for total choles-
terol (P .019), but differences did not persist on post hoc
testing. Compositional analysis of IDL and LDL (Supple-
mental Table 1) indicated thatmeasures ofTGenrichment
increased over gestation and declined in the postnatal pe-
riod, but there was no effect of maternal BMI. TimeBMI
interactions were evident for the plasma TG (P  .002)
andVLDLmass (P .013) concentrations (Table 2), with
the normal-weight and obese groups significantly differ-
ent at the nadirs in T1 and in the postnatal period but
reaching similar peak levels in late gestation.
VLDL subfraction concentration and composition
Plasma VLDL-1 and VLDL-2 increased from T1 to T3
and declined in the postnatal period (P  .001) (Table 3).
Maternal obesity status had a significant impact on these
changes (P .044 and P .044, respectively). The ratio of
VLDL-1 to VLDL-2 was not influenced by either time of
samplingorBMI.Therewasaninteractionbetweentimeand
BMI for VLDL-1 with a 3-fold higher postnatal level of
VLDL-1 in obese compared with normal-weight women.
The TG-carrying capacity of VLDL-1 and VLDL-2 also in-
creased over gestation, and this remained high in the post-
natal period (P .001 compared with T1 levels), and there
was no impact of maternal obesity (Supplemental Table 1).
Table 2. Maternal Plasma Lipid and Lipoprotein Concentrations During and After Pregnancy According to the
World Health Organization BMI Category
Time of
Sampling
Normal
Weight Overweight Obese P Time P BMI P TimeBMI
Total cholesterol, mmol/L* T1 4.31 (0.60) 4.65 (0.77) 4.75 (0.97) .001 .88 .019
T2 5.95 (1.10) 6.09 (0.78) 5.82 (1.06)
T3 6.42 (0.84) 6.07 (1.01) 5.84 (0.97)
PN 3.93 (0.69) 4.13 (0.59) 4.49 (1.08)
LDL cholesterol, mmol/L* T1 2.49 (0.43) 2.77 (0.72) 2.96 (0.93) .001 .83 .11
T2 3.85 (0.89) 3.85 (0.85) 3.79 (0.97)
T3 4.13 (0.68) 3.86 (1.10) 3.77 (1.03)
PN 2.34 (0.62) 2.52 (0.48) 2.87 (1.02)
Triglyceride, mmol/L* T1 1.07 (0.32)a 1.34 (0.43)a,b 1.57 (0.63)b .001 .030 .002
T2 2.02 (0.87) 2.50 (0.66) 2.45 (0.94)
T3 3.05 (1.05) 2.86 (1.02) 2.80 (0.86)
PN 0.82 (0.28)a 1.16 (0.42)a,b 1.59 (0.82)b
NEFA, mmol/L* T1 0.27 (0.42) 0.12 (0.15) 0.25 (0.27) .26 .59 .74
T2 0.15 (0.19) 0.19 (0.14) 0.24 (0.34)
T3 0.21 (0.23) 0.21 (0.14) 0.21 (0.13)
PN 0.26 (0.17) 0.18 (0.20) 0.22 (0.21)
VLDL, mg/dL* T1 68 (26)a 86 (33)a,b 113 (66)b .001 .016 .013
T2 173 (101) 176 (54) 202 (91)
T3 202 (123) 220 (103) 205 (80)
PN 55 (27)a 83 (40)a,b 118 (69)b
IDL, mg/dL* T1 58 (19) 71 (29) 85 (63) .001 .44 .30
T2 126 (54) 116 (29) 136 (52)
T3 146 (51) 153 (59) 157 (101)
PN 70 (29) 90 (21) 82 (32)
LDL, mg/dL T1 74 (22) 80 (24) 89 (34) .001 .98 .06
T2 140 (46) 109 (33) 117 (47)
T3 111 (19) 121 (59) 101 (37)
PN 74 (19) 80 (26) 84 (30)
Abbreviations: P BMI, association with BMI category; P Time, association of lipid/lipoprotein parameters over time; P TimeBMI, interaction between
time and BMI, using a univariate split-plot approach, repeated-measures analysis. Mean (SD) are shown. Trimester values are as follows: T1, 12.5
(1.2) weeks; T2, 26.1 (1.3) weeks; T3, 35.5 (1.3) weeks; PN, 17.1 (2.9) weeks after delivery. Where the interaction between time and BMI was
significant (P  0.05), 1-way ANOVA and Tukey Kramer post hoc tests were conducted. Different superscript letters indicate differences between
BMI categories at a particular time point using post hoc Tukey test. Statistical analysis was carried out on *log transformed data.
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LDL subfraction concentration and distribution
The mass of large, light LDL-I and small, dense LDL-III
changed over gestation, whereas LDL-II mass was un-
changed (Table 3). LDL-I mass was lowest at T1 (P .001)
and LDL-III mass was higher at T2 (P .001) and T3 (P
.07) compared with both T1 and postnatal samples (1 way
ANOVAplus post hoc testing using the whole group, Table
3). Therewas no overall impact ofmaternal obesity on LDL
subfraction concentrations and no interaction betweenLDL
subfraction concentration and obesity. Figure 1 shows the
percentage distribution of LDL subfractions over pregnancy
and postnatally. By the end of T3, obese women had a sig-
nificantly higher proportion of small, dense LDL-III (P 
.014) and a significantly lower proportion of intermediate
LDL-II (P .002) than normal-weightwomen.Overweight
women had LDL subfraction distributions between those of
the normal and obesewomen. In T3, 35%of obese, 14%of
overweight, and none of normal-weight women had an
atherogenic LDL subfraction profile, pattern B (greater than
50% LDL-III). This shift in distribution had resolved by 3
monthspostnatally,but therewas still ahigherproportionof
LDL-I particles in normal-weight compared with obese
women (Fig. 1).
Associations between plasma lipoprotein lipase
mass, hormone, and lipoprotein response to
pregnancy
Plasma LPL mass and hormone concentrations are
shown (Table 4). S447X LPL genotype was significantly
associated with LPL mass (P  .0001) as described (25).
LPL mass declined over gestation, independent of geno-
type, reaching a nadir in T3 but there was no impact of
maternal BMI. Plasma estradiol, SHBG, insulin, HOMA,
and leptin (Supplemental Fig. 2) increased over pregnancy
and declined in the postnatal period (P  .001), whereas
plasma adiponectin decreased during pregnancy (P 
.001) (Supplemental Fig. 2). Plasmaglucose increaseddur-
ing pregnancy and remained elevated in the postnatal pe-
riod (P  .001), and there was an impact of BMI, with
normal-weight women having lower T1 glucose levels
(P .038).Higher BMIwas associatedwith lower plasma
estradiol (P  .017), SHBG (P  .038), and adiponectin
(P  .002) but higher leptin (P  .001). There was a
timeBMI interaction for estradiol and leptin but not
adiponectin.
Plasma LPL mass was inversely associated with TG
across all time points in the total group (r  0.71, r2
Table 3. Maternal VLDL and LDL Subfraction Concentrations During and After Pregnancy According to the World
Health Organization BMI Category
Time of
Sampling
Normal
Weight Overweight Obese P Time P BMI P TimeBMI
VLDL-1, mg/dL# T1 15 (8) 21 (12) 26 (15) .001 .044 .010
T2 43 (29) 44 (21) 52 (26)
T3 51 (30) 51 (29) 49 (24)
PN 13 (9)a 20 (10)a,b 40 (29)b
VLDL-2, mg/dL* T1 53 (18) 66 (24) 87 (61) .001 .044 .12
T2 130 (74) 132 (39) 150 (77)
T3 152 (97) 170 (83) 156 (72)
PN 41 (23) 64 (36) 77 (47)
VLDL-1/VLDL-2 Ratio* T1 0.27 (0.10) 0.31 (0.15) 0.34 (0.19) .13 .28 .46
T2 0.33 (0.17) 0.33 (0.12) 0.39 (0.22)
T3 0.36 (0.14) 0.33 (0.19) 0.37 (0.22)
PN 0.38 (0.27) 0.38 (0.26) 0.55 (0.25)
LDL-I, mg/dL# T1 22 (10) 14 (12) 17 (12) .001 .15 .34
T2 20 (12) 19 (17) 20 (13)
T3 18 (7) 20 (70) 19 (11)
PN 48 (25) 42 (25) 29 (16)
LDL-II, mg/dL# T1 81 (34) 71 (26) 68 (24) .053 .070 .19
T2 92 (29) 70 (42) 80 (32)
T3 107 (27) 84 (34) 70 (27)
PN 101 (47) 76 (44) 104 (54)
LDL-III, mg/dL# T1 35 (22) 32 (20) 40 (26) .001 .12 .20
T2 50 (35) 62 (37) 64 (34)
T3 35 (21) 49 (20) 60 (28)
PN 28 (13) 25 (33) 62 (68)
Abbreviations: P BMI, association with BMI category; P Time, association of lipid/lipoprotein parameters over time; P TimeBMI, the interaction between
time and BMI, using a univariate split-plot approach, repeated-measures analysis. Mean (SD) are shown. Trimester values are as follows: T1, 12.5 (1.2)
weeks; T2, 26.1 (1.3) weeks; T3, 35.5 (1.3) weeks; PN, 17.1 (2.9) weeks after delivery. Where the interaction between time and BMI was significant
(P 0.05), 1-way ANOVA and Tukey Kramer post hoc tests were conducted. Different superscript letters indicate differences between BMI categories at
a particular time point using post hoc Tukey test. Statistical analysis was carried out on *log or #square root transformed data.
J Clin Endocrinol Metab, February 2013, 98(2):643–652 jcem.endojournals.org 647
adjusted 50.1%, P  .001); an association that was
strengthened by the inclusion of LPL S447X genotype in
the model (r2 adjusted 84.6%, P  .001). The LPL re-
sponse to pregnancy was not associated with the TG re-
sponse to pregnancy (independent of S447X genotype).
Obese mothers had lower estradiol concentrations than
normal-weight women in T2 and T3 and higher leptin
levels at all time points. Incremental area under the curve
(AUC) total TG (r2 adjusted 25%, P  .001) (Fig. 2A),
VLDL cholesterol (15%, P  .006), VLDL-1 (13%, P 
.015), and VLDL-2 (22%, P  .002) were positively as-
sociated with incremental AUC plasma estradiol. Incre-
mental AUC insulin (or HOMA) did not explain the vari-
ation in TG-rich lipoprotein concentrations or in
incremental AUC leptin or adiponectin. Incremental AUC
adiponectin was negatively associated with incremental
AUC LDL-III mass (17%, P  .013) (Fig. 2B). Maternal
booking BMI (P  .004), plasma leptin in T3 (P  .003)
and adiponectin (P  .010) explained a total of 31% of
variance in the relative proportion of small, dense LDL.
None of the othermeasured variables contributed to these
associations in multivariate analysis.
Discussion
The concentration of all plasma lipids and lipoprotein
fractions increased over pregnancy, with the exception of
NEFA. The changes in total cholesterol, total TG, VLDL,
and LDL represent the physiological hyperlipidemic ad-
aptation to pregnancy, in which lipids are mobilized into
the maternal circulation to supply fuel and essential nu-
trients for the fetus. Maternal obesity
was associated with higher plasma lev-
els of TG, VLDL-1, and VLDL-2 pre-
dominantly at T1 and 17 weeks after
delivery.By later gestations, plasmaTG
and TG-rich lipoproteins appeared to
reach the same maximal level. This in-
dicates that obese mothers are less met-
abolically flexible, in terms of the ex-
tent of the metabolic adaptation to
pregnancy, than their normal-weight
counterparts. Estradiol incremental AUC
was significantly associated with plasma
TG, VLDL-cholesterol, VLDL-1, and
VLDL-2 response to pregnancy with no
change in VLDL-1 to VLDL-2 total mass
ratio during pregnancy. These data indi-
cate that estradiol up-regulates the secre-
tion of both VLDL subfractions equally
from the liver to promote the gestational
increase in plasma TG.
We were unable to assess the relative contributions to
the gestational increase in the VLDL-2 mass of direct syn-
thesis of VLDL-2 by the liver and conversion of VLDL-1
to VLDL-2 by lipolysis. Kinetic studies in nonpregnant
women show that production rates of both large and small
VLDL fractions are increased by low-dose oral contracep-
tives (26). Our data are also consistent with the strong
relationship observed between the gestational rise in es-
tradiol and the increment in plasma TG in a small group
of normal-weight pregnant women (15). We found an in-
teraction between BMI and time for estradiol, with obese
women having significantly lower estradiol levels in late
pregnancy than normal-weight women. This is likely due
to the sequestration of estradiol in adipose tissue (27). It is
notable that measures of insulin resistance did not con-
tribute to gestational changes in VLDL concentration.
This suggests that the effects of estradiol on VLDL pro-
duction by the liver may override any insulin effects of
VLDL production during pregnancy.
The VLDL compositional data suggest that as preg-
nancy progresses, all TG-rich lipoprotein fractions carry
more TG molecules per particle. Although plasma LPL
mass was inversely correlated with TG at all time points,
LPL incrementalAUC(which is negative due todecreasing
LPL levels during pregnancy) was not associated with
plasma TG response to pregnancy. This finding was in-
dependent of the influence of the S447X LPL polymor-
phism, which, for as-yet-unknown reasons, has a large
influence on plasma LPL mass, postheparin LPL activity,
and plasma TG levels (25). LPL mass is a poor surrogate
of total lipase activity because it ismostly inactive (22, 23).
Trimester 1
80%
100%
Trimester 2
80%
100%
0%
20%
40%
60% % LDL-III
% LDL-II
% LDL-I 
0%
20%
40%
60% % LDL-III
% LDL-II
% LDL-I 
Healthy Obese Healthy Obese
Trimester 3
80%
100%
P=0.014
Post natal
100%
20%
40%
60% % LDL-III
% LDL-II
% LDL-I 
P=0.002
20%
40%
60%
80%
% LDL-III
% LDL-II
% LDL-I 
P=0.041
0%
Healthy Obese
0%
Healthy Obese
Figure 1. LDL subfraction distribution during pregnancy. Percentage abundance of LDL-I,
LDL-II, and LDL-III in normal-weight and obese individuals in each trimester of pregnancy and
3 months postnatally. Differences in percentage LDL subfraction between normal-weight and
obese mothers at each sampling point was carried by 1-way ANOVA and post hoc Tukey
Kramer tests.
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It has been suggested in the nonpregnant that low LPL
mass is a marker of metabolic syndrome and that this
reflects the low rate of LPL synthesis by adipocytes in the
insulin-resistant state (28, 29). However, we did not ob-
serve a BMI effect on LPL mass in pregnancy. We specu-
lated that steady-state plasma levels of TG are determined
predominantlyby increasedVLDLproduction in response
to estradiol, rather than by LPL-mediated clearance.
During pregnancy, mass levels of LDL-I and LDL-II
were unchanged, but the mass of LDL-III increased, par-
ticularly in overweight and obese individuals. This was
reflected in a significantly higher proportion of LDL-III in
obese mothers in T3. Large LDL subfractions are remod-
eled into smaller, denser LDL-III as plasmaTG rises above
a threshold of 1.5 mmol/L (12), an effect that is facilitated
by hepatic lipase and cholesteryl ester transfer protein
(30). Obese mothers have raised baseline TG and conse-
quently reach the threshold concentration of TG earlier
and more easily than normal-weight women. A high pro-
portion of the overweight and obese women had greater
than50%LDL-III inT3.This indicates a shift in their LDL
subfraction profile from a healthy pattern A phenotype to
an atherogenic pattern B phenotype (21). Small, dense
LDL-III particles are susceptible to oxidation, and oxi-
dizedLDL is inversely associatedwith vascular function in
subjects exhibiting cardiovascular risk factors (31). A pre-
dominance of LDL-III is a hallmark of conditions inwhich
there is an accumulation of ectopic liver fat, such as non-
alcoholic fatty liver disease (32) and type 2 diabetes (14).
Thirty-five percent of the obese pregnant women had an
LDLpatternBprofile byT3.This suggests that a subgroup
of obese women are less able to cope with the gestational
increase in TG, are predisposed to store fat ectopically,
andare at riskofGDMandPE (9). In theory, fatty liver has
Table 4. Maternal Plasma LPL and Hormone Levels During and After Pregnancy According to the World Health
Organization BMI Category
Time of
Sampling
Normal
Weight Overweight Obese P Time P BMI P TimeBMI
LPL mass, ng/mL* T1 43 (16) 32 (10) 35 (14) .001 .14 .32
T2 29 (12) 22 (8) 21 (8)
T3 23 (11) 19 (5) 21 (7)
PN 46 (11) 47 (11) 45 (14)
Estradiol, ng/mL# T1 3.1 (1.8) 2.8 (1.4) 2.5 (1.4) .001 .017 .023
T2 12.2 (4.0)a 10.0 (3.3)a,b 8.4 (3.3)b
T3 20.0 (13.6)a 13.4 (3.1)a,b 11.5 (3.2)b
PN 0.05 (0.03) 0.03 (0.02) 0.11 (0.21)
SHBG, mmol/L T1 221 (38) 218 (34) 191 (36) .001 .038 .23
T2 309 (99) 251 (33) 252 (63)
T3 285 (66) 259 (23) 253 (26)
PN 59 (27) 54 (11) 68 (52)
Insulin, mU/L* T1 16 (7) 20 (23) 25 (22) .001 .17 .85
T2 32 (29) 38 (26) 58 (41)
T3 54 (46) 44 (45) 48 (29)
PN 19 (12) 31 (52) 27 (18)
Glucose, mmol/L* T1 4.0 (0.9) 4.8 (1.1) 5.0 (0.7) .001 .038 .069
T2 4.6 (0.7) 5.5 (1.2) 5.6 (1.2)
T3 5.2 (0.8) 5.2 (0.9) 5.4 (1.2)
PN 5.2 (1.0) 5.3 (0.7) 5.4 (0.6)
HOMA* T1 2.9 (1.6) 5.0 (0.3) 6.0 (1.0) .001 .12 .77
T2 6.8 (5.9) 10.5 (10.0) 15.4 (11.6)
T3 14 (13) 11 (14) 13 (11)
PN 4.5 (3.7) 7.4 (11.9) 6.9 (5.1)
Leptin, ng/mL* T1 12 (5)a 18 (6)b 40 (13)c .001 .001 .010
T2 17 (12)a 22 (10)a 44 (20)b
T3 18 (18)a 24 (14)a 43 (21)b
PN 12 (8)a 11 (5)a 39 (14)b
Adiponectin, g/mL* T1 10.9 (3.1) 10.2 (2.5) 7.6 (3.4) .001 .002 .42
T2 9.3 (3.2) 8.3 (2.4) 6.3 (2.8)
T3 9.1 (3.4) 8.0 (2.4) 6.8 (2.3)
PN 10.1 (5.0) 8.2 (1.7) 6.5 (2.8)
Abbreviations: P BMI, association with BMI category; P Time, association of lipid/lipoprotein parameters over time; P TimeBMI, the interaction
between time and BMI, using a univariate split-plot approach, repeated-measures analysis. Mean (SD) are shown. Trimester values are as follows:
T1, 12.5 (1.2) weeks; T2, 26.1 (1.3) weeks; T3, 35.5 (1.3) weeks; PN, 17.1 (2.9) weeks after delivery. Where the interaction between time and BMI
was significant (P  0.05), 1-way ANOVA and Tukey Kramer post hoc tests were conducted. Different superscript letters indicate differences
between BMI categories at a particular time point using post hoc Tukey test. Statistical analysis was carried out on *log or #square root
transformed data.
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been linked to the formation of small, dense LDL through
the production and release of TG-enriched VLDL (14).
However, there was no evidence in the present study to
support a link between the increase in LDL-III and large
TG-rich VLDL in obese women. Instead, the relativemass
and proportion of LDL-III in T3 were associated with
plasma adiponectin levels, and also maternal obesity, lep-
tin, and adiponectin, in respective multivariate models.
The rise of leptin levels to a T2 peak and the fall of
adiponectin to a T3 nadir in pregnancy have previously
been reported (33, 34). Although these changes are sug-
gested to be due to gestational maternal fat accumulation,
we found no evidence that maternal insulin resistance
played a role, and others suggested that
additional factors determine at least
leptin levels in pregnancy (35). Adi-
ponectin levels are reduced in obesity
and lower still in nonalcoholic fatty
liver disease (36). Adiponectin has been
reported to reduce fatty acid synthesis
via sterol regulatory element-binding
protein-1c, activate fatty acid oxida-
tion via AMP kinase, and have antiin-
flammatory andantioxidative effects at
the liver (37). The gestational levels of
adiponectin reachedby theobesepregnant
women (mean 6.8, SD2.3g/mL) are in a
similar range to obese individuals with
nonalcoholichepaticsteatosis(5.6g/mL),
whereas normal-weight pregnant women
and obese individuals without nonalco-
holichepatic steatosishave similar levelsof
approximately 10–11g/mL (36).
PlasmaNEFA levelswere stable over
pregnancy, as has been observed for
nonpregnant obesity, insulin resis-
tance, and well-controlled type 2 dia-
betes (38). Although NEFA concentra-
tion does not change this provides no
information on NEFA flux; it merely
suggests that rates of entry of NEFA
into the blood via lipolysis and exit by
uptake into tissues are equal. There
were no associations betweenmaternal
obesity and cholesterol concentrations,
levels and composition of cholesterol-
rich lipoproteins or plasmaNEFA.This
observation is analogous to nonpreg-
nant obese individuals, in whom the
predominant phenotype is ofmetabolic
syndrome characterized by raised TG,
low high-density lipoprotein levels, but
often normal cholesterol levels.
Most lipid changes in response to pregnancy had re-
solved to baseline levels by 3 months after pregnancy.
However, TG enrichment of VLDL-1 and VLDL-2 re-
mained high postnatally. Furthermore, LPLmass concen-
tration was significantly higher in the postnatal period
than at any time during pregnancy. This may represent an
adaptation for breast-feeding, facilitating the use of TGby
mammary tissue. Unfortunately, we do not have a record
of breast-feeding activity in our women. We also showed
that VLDL-1 levels remain significantly elevated in obese
women after pregnancy. This could be explained by the
relative loss of estradiol and a reemergence of the predom-
Figure 2. Univariate association between plasma response to pregnancy of plasma TG and
estradiol and LDL-III mass and adiponectin. A, Incremental AUC total TG was associated with
incremental AUC plasma estradiol (r2 adjusted 25%, P  .001). B, Incremental AUC
adiponectin was associated with incremental AUC LDL-III mass (r2 adjusted 17%, P  .013).
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inant effect of insulin resistance, with resulting failure to
suppress VLDL-1 secretion from the liver (26).
The strengths of this study are the longitudinal design,
wide range of BMI, larger numbers than reported previ-
ously, and concurrent measurements of lipids and hor-
mones. There are a variety of methods for separating LDL
subfractions, ranging from the specialist analytical or den-
sity gradient ultracentrifugation andnuclearmagnetic res-
onance to more accessible gradient and tube gel electro-
phoresis. Although a definitive classification of LDL
subfractions has not been established, the method used
here, density gradient electrophoresis, identifies the classic
LDL-I, LDL-II, and LDL-III subfractions that have an es-
tablished link to metabolic disease risk (12). A weakness
is the lack of direct enzyme activity measurements. We
were unable to measure activities of LPL (and hepatic
lipase) in plasma because the iv injection of heparin to
release the functional pool of lipases from the endothelium
is ethically not acceptable in pregnant women. Further-
more, we lacked detailed dietary and breast-feeding data,
and the absence of a kinetic analysis of lipoprotein me-
tabolism left us unable to comment on the interconversion
of VLDL-1 to VLDL-2.
Increased plasma levels of TG and cholesterol is an
essential adaptation to pregnancy. Normal-weight moth-
ers enter pregnancy with a healthy lipid profile and in-
crease levels of cholesterol and TG-rich lipoproteins to a
maximum, which decline to prepregnancy levels postna-
tally.Obesemothers begin pregnancywith higher levels of
TG-rich lipoproteins, and these rise to the same level as
normal-weight women by late gestation. Although in
quantitative terms the plasma lipids of obese mothers are
equivalent to thatof theirnormal-weight counterparts, the
quality of their lipidsmay convey greater cardiometabolic
risk due to the formation of small, dense LDL. Not all
obese women develop metabolic complications of preg-
nancy. We speculate that a subset of obese women are
susceptible to the accumulation of ectopic fat in the liver,
perhaps due to low adiponectin levels and accompanying
adverse changes in LDL composition. Small, dense LDL
hasbeenobserved inbothPEandGDM(17, 18), and these
conditions are susceptible to fatty liver in pregnancy (39).
Ourdata suggest that a subset of obesewomen, at high risk
for PE and GDM, may be identified for targeted interven-
tion. Such intervention may include specific dietary ma-
nipulations, such as long chain n-3 polyunsaturated fatty
acid supplementation, which are known to exert a favor-
able impact on the pathways described herein. Response
to pregnancy may also reveal at an early stage in a wom-
an’s life her susceptibility to metabolic abnormalities and
fatty liver later in life (40).
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